Top Markets
#1 DogBull DogBull +108.52%
#2 MarsCoin MarsCoin +77.08%
#3 Siacoin Siacoin +54.30%
#4 ADO Protocol ADO Protocol +52.57%
#5 The Bitcoin Bull The Bitcoin Bull +28.16%
#6 Ontology Gas Ontology Gas +25.60%
#7 Apertum Apertum +16.37%
#8 Pons Pons +14.02%
#9 Useless Coin Useless Coin +13.13%
#10 Arowana Arowana +12.73%
Coin of the day
DogBull DogBull
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Classificação em ações #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Preço da ação
$4.74
Última sincronização: 2026-08-31
Valor de mercado
$372.19M
Variação (1 dia)
-2.47%
Variação (1 ano)
-1.04%
País
US
Negociar Lexeo Therapeutics, Inc. Common Stock (LXEO)

Categoria

Healthcare
Receita da Lexeo Therapeutics, Inc. Common Stock (LXEO)
Receita em Sep 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Lexeo Therapeutics, Inc. Common Stock, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Lexeo Therapeutics, Inc. Common Stock de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH